Table 4 Characteristics of AML studied cases in comparison with lncRNA ZEB2-AS1 expression groups
lncRNA ZEB2-AS1 expression | |||
|---|---|---|---|
Characteristic | Low expression (n = 42) | High expression (n = 27) | P value |
Age (years) | 47 ± 13 | 49 ± 16 | 0.581 |
Sex | |||
Males | 24 (57.1) | 16 (59.3) | 0.862 |
Females | 18 (42.9) | 11 (40.7) | 0.581 |
Initial TLC (× 103) | 17.4 (0.6–316) | 32 (0.3–403) | 0.376 |
Initial HGB | 7.9 ± 1.9 | 7.9 ± 2 | 0.998 |
Initial PLT (× 103) | 43 (5–208) | 54 (6–135) | 0.966 |
Initial PB blasts (%) | 55 (0–100) | 70 (0–90) | 0.279 |
Initial BMA blast (%) | 70 (20–98) | 75 (20–96) | 0.226 |
Initial cellularity | |||
Hypocellularity | 1 (2.4) | 1 (3.7) | 1.0 |
Hypercellularity | 35 (83.3) | 22 (81.5) | |
Normocellularity | 6 (14.3) | 4 (14.8) | |
Hepatomegaly | 7 (16.7) | 7 (25.9) | 0.351 |
Splenomegaly | 6 (14.3) | 6 (22.2) | 0.396 |
Lymphadenopathy | 11 (26.2) | 13 (48.1) | 0.062 |
Fever | 20 (47.6) | 13 (48.1) | 0.966 |
Positive CD34 | 19 (45.2) | 17 (63) | 0.150 |
Positive HLA-DR | 26 (61.9) | 14 (51.9) | 0.409 |
Positive MPO (cyto) | 36 (85.7) | 23 (85.2) | 0.951 |
Positive CD33 | 37 (88.1) | 25 (92.6) | 0.697 |
Positive CD13 | 36 (85.7) | 23 (85.2) | 0.951 |
Positive CD117 | 28 (66.7) | 21 (77.8) | 0.321 |
Positive CD14 | 6 (14.3) | 10 (37) | 0.029 |
Positive CD4 | 3 (7.1) | 4 (14.8) | 0.42 |
Positive CD11c | 11 (26.2) | 8 (29.6) | 0.755 |
Positive CD64 | 13 (31) | 9 (33.3) | 0.836 |
Positive CD61 | 1 (2.4) | 1 (3.7) | 1.0 |
Positive Cd 7 | 2 (4.8) | 1 (3.7) | 1.0 |
Abnormal cytogenetics | 21 (53.8) | 11 (52.4) | 0.914 |
Negative FLT-ITD | 34 (81) | 19 (70.4) | 0.309 |
Positive FLT-ITD | 8 (19) | 8 (29.6) | |
Wild NPM | 41 (97.6) | 23 (85.2) | 0.073 |
Mutant NPM | 1 (2.4) | 4 (14.8) | |
t(8;21) | 4 (9.5) | 1 (3.7) | 0.641 |
PML/RARA | 3 (7.1) | 2 (7.4) | 1.0 |
t(16;16)/inv16 | 1 (2.4) | 0 (0) | 1.0 |
t(9:22) | 2 (4.8) | 0 (0) | 0.517 |
FAB subtypes | |||
M0 | 0 (0) | 1 (3.7) | 0.778 |
M1 | 8 (19) | 5 (18.5) | |
M2 | 16 (38.1) | 7 (25.9) | |
M3 | 3 (7.1) | 3 (11.1) | |
M4 | 9 (21.4) | 8 (29.6) | |
M5 | 5 (11.9) | 2 (7.4) | |
M6 | 0 (0) | 0 (0) | |
M7 | 1 (2.4) | 1 (3.7) | |
Genetic risk (ELN 2017) | |||
Favorable | 9 (21.4) | 6 (22.2) | 0.966 |
Intermediate | 20 (47.6) | 12 (44.4) | |
Poor | 13 (31) | 9 (33.3) | |
Treatment response | |||
BMA blast on day 14 | 2 (0–77) | 1 (0–90) | 0.304 |
BMA blast on day 28 | 3 (0–80) | 2 (0–88) | 0.398 |